ArticleTheranostics2020
Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- New Strategies in Comprehensive Melanoma Treatment: Applications, Potential, and Challenges of Hydrogels.International journal of nanomedicine · 2025Pooled it
- Integrin-mediated mechanotransduction in the tumor microenvironment: macrophage-centered signaling mechanisms and immune remodeling.Journal of translational medicine · 2026Review
- SPP1Cell death & disease · 2026Article
- Peritoneal effusion as a marker of disease severity in secondary hemophagocytic lymphohistiocytosis: Clinical and immunological insights.SAGE open medicine · 2026Article
- Targeting Tumor-Associated Macrophages to Reshape the Immuno-Mechanical Landscape: Molecular Mechanisms and Therapeutic Strategies.International journal of biological sciences · 2026Review
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration.Materials today. Bio · 2025Review
- Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy.Gels (Basel, Switzerland) · 2025Review
- Tailoring Therapy: Hydrogels as Tunable Platforms for Regenerative Medicine and Cancer Intervention.Gels (Basel, Switzerland) · 2025Review
- Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook.Journal of nanobiotechnology · 2025Review
- Recent advances of injectable in situ-forming hydrogels for preventing postoperative tumor recurrence.Drug delivery · 2024Review
- Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment.Journal of nanobiotechnology · 2024Article
- Applications of self-assembled peptide hydrogels in anti-tumor therapy.Nanoscale advances · 2024Review
- A parathyroid hormone related supramolecular peptide for multi-functionalized osteoregeneration.Bioactive materials · 2024Article
- The complex role of IL-10 in malignant ascites: a review.Cancer immunology, immunotherapy : CII · 2024Review
- Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.International journal of nanomedicine · 2024Review
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy.Bioactive materials · 2024Review
- Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer.Advanced drug delivery reviews · 2023Review
- Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simultaneously targeted treatment of tumor cells and their surrounding growth-supporting immune cells is a promising strategy to reshape immunosuppressive tumor microenvironment (TME) and potentiate host innate and adaptive antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.